Macular Degeneration Association

Therapeutic Areas: Oncology | Hematology

Hematologic Neoplasms Clinical Trials

A listing of Hematologic Neoplasms medical research trials actively recruiting patient volunteers. Use the filters below to narrow your search results.

 

Arizona

Scottsdale Arizona 85259-5499

A clinical trial to evaluate treatments using SAR650984, pomalidomide and dexamethasone for patients with Haematological Malignancy

Scottsdale Arizona 85258

A Phase 1 clinical study for patients with Hematologic Neoplasms

Scottsdale Arizona 85259

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Scottsdale Arizona 85258

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

California

Duarte California 91010

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Los Angeles California 90027

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Stanford California 94305

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Colorado

Aurora Colorado 80045

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Florida

Miami Florida 33136

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Sarasota Florida 34232

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Illinois

Chicago Illinois 60611

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Chicago Illinois 60637

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Maryland

Baltimore Maryland 21287

A Phase 1 clinical study for patients with Hematologic Neoplasms

Massachusetts

Boston Massachusetts 02114

A clinical trial to evaluate treatments using SAR650984, pomalidomide and dexamethasone for patients with Haematological Malignancy

Boston Massachusetts 02115

A clinical trial to evaluate treatments using SAR650984, pomalidomide and dexamethasone for patients with Haematological Malignancy

Boston Massachusetts 02215

A Phase 1 clinical study for patients with Hematologic Neoplasms

Boston Massachusetts 02215

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Boston Massachusetts 02114

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Michigan

Ann Arbor Michigan 48109

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Missouri

St. Louis Missouri 63110

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

New York

New York New York 10021

A Phase 1 clinical study for patients with Hematologic Neoplasms

New York New York 10065

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

New York New York 10065

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

North Carolina

Charlotte North Carolina 28204

A clinical trial to evaluate treatments using SAR650984, pomalidomide and dexamethasone for patients with Haematological Malignancy

Ohio

Cleveland Ohio 44106

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Columbus Ohio 43210

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Oregon

Portland Oregon 97239

A Phase 1 clinical study for patients with Hematologic Neoplasms

South Carolina

Greenville South Carolina 29605

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Tennessee

Nashville Tennessee 37203

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Nashville Tennessee 37232

Patients are needed to participate in a clinical research study evaluating CC-486 (Oral Azacitidine) and Vidaza

Texas

Dallas Texas 75390

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Dallas Texas 75390

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Houston Texas 77030

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Houston Texas 77030

A Phase 1 clinical study for patients with Hematologic Neoplasms

Houston Texas 77030

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

San Antonio Texas 78229

A Phase 1 clinical study for patients with Hematologic Neoplasms

Virginia

Fairfax Virginia 22031

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Washington

Seattle Washington 98109

A Phase 1 clinical study for patients with Hematologic Neoplasms

France

Bordeaux 33000

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Lille

Patients are needed to participate in a clinical research study of OTX015 to evaluate Acute Leukemia or Other Hematological Malignacies

Paris 75014

A clinical research study of Vemurafenib for the treatment of Solid Tumors, Hematologic Cancers or Metastatic Cancers

Paris

Patients are needed to participate in a clinical research study of OTX015 to evaluate Acute Leukemia or Other Hematological Malignacies

Villejuif Ile de France 94805

A clinical research study of Crizotinib for the treatment of Hematologic Cancers, Solid Tumors or Metastatic Cancer

Villejuif 94800

Patients are needed to participate in a clinical research study evaluating AG-221 for the treatment of Relapsed and/or Primary Refractory AML as Defined by WHO Criteria, Untreated AML, ≥60 Years of Age and Not a Candidate for Standard Therapy or Recurrent or Refractory Myelodysplastic Syndrome

Germany

Frankfurt 60590

A clinical trial seeking patients for a research study for the treatment of Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML), Myelodysplastic Syndromes (MDS) or Juvenile Myelomonocytic Leukaemias (JMML)

Munster 48129

A clinical trial seeking patients for a research study for the treatment of Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML), Myelodysplastic Syndromes (MDS) or Juvenile Myelomonocytic Leukaemias (JMML)

Israel

Tel Aviv

A clinical research study of Ibrutinib and Nivolumab for the treatment of Hematologic Neoplasms, Hematologic Malignancies

Italy

Rome 00161

A clinical trial to evaluate treatments using BPX-501 T cells and AP1903 for patients

Torino

Patients are needed to participate in a clinical research study of OTX015 to evaluate Acute Leukemia or Other Hematological Malignacies

Japan

Fukuoka

A Phase 1 clinical study for patients with Blood Cancer or Advanced B Cell Malignancies